|
|
|
Volumn 9, Issue 1, 1999, Pages
|
|
Treatment advances for CMV retinitis
|
|
Author keywords
Antiretroviral therapy; CMV retinitis; Cytomegalovirus (CMV); Infection, eye; Infection, opportunistic
|
|
Indexed keywords
ANTIRETROVIRUS AGENT;
CIDOFOVIR;
DIDANOSINE;
EMLA;
FOSCARNET SODIUM;
GANCICLOVIR;
LIDOCAINE;
NELFINAVIR;
PROBENECID;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
STAVUDINE;
CYTOSINE;
DRUG DERIVATIVE;
FOSCARNET;
ORGANOPHOSPHORUS COMPOUND;
PHOSPHONIC ACID DERIVATIVE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
AIDS RELATED COMPLEX;
ARTICLE;
CENTRAL VENOUS CATHETER;
CYTOMEGALOVIRUS;
DISEASE COURSE;
DRUG ABSORPTION;
DRUG DELIVERY SYSTEM;
EYE TOXICITY;
HUMAN;
INCIDENCE;
INTRAOCULAR DRUG ADMINISTRATION;
INTRAVENOUS DRUG ADMINISTRATION;
ORAL DRUG ADMINISTRATION;
RETINITIS;
TREATMENT PLANNING;
CYTOMEGALIC INCLUSION BODY DISEASE;
DRUG COMBINATION;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
CYTOMEGALOVIRUS INFECTIONS;
CYTOSINE;
DRUG THERAPY, COMBINATION;
FOSCARNET;
GANCICLOVIR;
HUMANS;
ORGANOPHOSPHORUS COMPOUNDS;
PHOSPHONIC ACIDS;
RETINITIS;
|
|
EID: 0033044666
PISSN: 10530894
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (3)
|
|
References (17)
|
